Male HRT for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Male HRT for Health & Longevity

Created on 07/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

For men who are genuinely testosterone-deficient with symptoms, the strongest evidence supports gains in muscle, bone strength, red blood cell production, and sexual desire; effects on fat, mood, blood sugar, energy, and thinking are smaller and less certain. In men with normal levels, benefits largely disappear while risks remain. Lifespan extension stays unproven. (Full Review)

Protocol

Confirm & Target
500–800 ng/dL trough
Start only after two morning low readings plus symptoms; aim mid-to-upper normal, not supraphysiologic
Injectable
100–200 mg every 1–2 weeks
Cypionate or enanthate intramuscularly; or 50–100 mg weekly/twice-weekly subcutaneously to smooth peaks; undecanoate every 10–14 weeks
Transdermal Gel
40–100 mg daily
1–2% gel applied in the morning to mimic the natural daily rhythm
Time to effect
Libido & Mood
3–6 weeks
Sexual desire and mood shift first
Muscle & Fat
3–6 months
Body-composition and metabolic changes
Bone Density
6–12 months+
Requires continuous use

Benefits

Contraindications
  • Active or suspected prostate or breast cancer
  • Uninvestigated PSA above ~4 ng/mL or rapidly rising PSA
  • Hematocrit above 54%
  • Untreated severe obstructive sleep apnea
  • Uncontrolled heart failure (NYHA Class III–IV)
  • Recent cardiovascular event (within 3–6 months)
  • Actively seeking to conceive
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban)
  • Blood-glucose-lowering drugs (insulin, sulfonylureas)
  • Corticosteroids (prednisone), sodium-retaining drugs
  • Over-the-counter agents (NSAIDs, DHEA)
  • Supplement interactions (DHEA, testosterone boosters, DIM, grape-seed extract, saw palmetto)
  • Additive-effect medications (aromatase inhibitors, anabolic-androgenic steroids, hCG)
    •

Risk & Side Effects

  • High: Erythrocytosis, suppressed sperm production & infertility, testicular atrophy
    •
  • Medium: Acne & oily skin, fluid retention, gynecomastia
    •
  • Low: Accelerated male-pattern hair loss, worsening obstructive sleep apnea, atrial fibrillation & cardiovascular events, prostate enlargement & PSA rise
    •
  • Speculative: Venous blood clots, accelerated prostate cancer progression
    •

Monitoring

Marker Target Why
Total testosterone 500–800 ng/dL (trough) Confirms adequate but not excessive dosing
Free testosterone ~1.5–2.5% of total; upper-normal The bioavailable fraction driving symptoms
Estradiol (sensitive) 20–40 pg/mL Detects excess aromatization (gynecomastia, fluid retention)
Hematocrit 40–50% Detects erythrocytosis, the main safety marker
PSA (prostate-specific antigen) <1.5 ng/mL (age-adjusted) Prostate safety surveillance
SHBG (sex hormone-binding globulin) 20–60 nmol/L Interprets free versus total testosterone
LH & FSH Suppressed on therapy Confirms exogenous effect and helps classify deficiency
HbA1c <5.4% Tracks the metabolic benefit and diabetes risk
Lipid panel LDL <100 mg/dL; HDL >45 mg/dL Monitors cardiovascular risk context

Cadence: Baseline, then ~3 and 6 months after starting or any dose change, then every 6–12 months once stable; more frequent blood-count and PSA checks in higher-risk men

Qualitative Assessment

  • Sexual desire and frequency of morning erections
  • Energy, drive, and motivation through the day
  • Mood stability and sense of wellbeing
  • Cognitive clarity and focus
  • Sleep quality (and any new snoring or breathing pauses)
  • Training performance, recovery, and body composition
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.